Greetings, and welcome to inTEST Corporation’s Third Quarter 2021 Financial Results. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded today. I'll now turn the call over to your host Deb Pawlowski, Investor Relations for inTEST Corporation. Thank you. You may begin.

Thanks, Melissa, and good morning everyone. We certainly appreciate your time today and your interest in inTEST Corporation. Here with me are Nick Grant, our President and CEO; and Duncan Gilmour, our Chief Financial Officer and Treasurer. You should have a copy of the third quarter 2021 financial results, which we released this morning before markets opened. If not, you can access the release, as well as the slides that will accompany our conversation today at our website www.intest.com. After our formal presentation, we will be opening the line for Q&A. If you'll turn to slide two in the deck, I will first review the safe harbor statement. You should be aware that we may make some forward-looking statements during the formal discussions, as well as during the Q&A session. These statements apply to future events that are subject to risks and uncertainties, as well as other factors that could cause actual results to differ materially from what is stated here today. These risks and uncertainties and other factors are provided in the earnings release, as well as with other documents filed with the Securities and Exchange Commission. You can find these documents on our website or at sec.gov. During today's call, we will also discuss some non-GAAP financial measures. We believe these will be useful in evaluating our performance. You should not consider the presentation of this additional information in isolation or as a substitute for results prepared in accordance with GAAP. We have provided reconciliation of non-GAAP measures with comparable GAAP measures in the tables that accompanied in today's release and in the slides. So with that, if you would please turn to slide three. I will turn it over to Nick to begin. Nick?

Thank you, Deb and good morning everyone. We delivered solid third quarter results that we believe demonstrate the successful execution of our five-point strategy, which is focused on driving growth, diversifying our markets and customer base, while ensuring we have the right talent to execute. In the quarter, we achieved year-over-year net revenue growth of 46% to $21.1 million. As global demand for our semiconductors continued to show relative strength and industrial sectors benefited from ongoing broad-based recovery. Of note, our Multimarket revenue grew 22% sequentially. Like many others, we continue to face supply chain constraints and inflationary pressures. We had an estimated $500,000 of finished goods that we were unable to ship in the quarter due to logistic challenges. Our teams have done an excellent job managing supplier and logistic challenges to fulfill orders. We continue to implement enhanced pricing to help overcome inflationary and expediting costs. The results of these efforts were reflected in our margins and profitability in the quarter, which were in our expected range. During the quarter, we generated $4.3 million in cash from operations, increasing our year-to-date total cash generated to $8.1 million. Cash on hand at the end of the quarter was nearly $19 million. In support of our organic and inorganic growth initiatives, we announced a couple of weeks ago that we executed a new extended and expanded credit agreement. Overall, this added liquidity allows us to capitalize on the attractive debt markets and provide additional financial flexibility to continue to pursue a robust pipeline of acquisition opportunities. Following that announcement, we successfully executed two acquisitions post third quarter close in October, Z-Sciences and Videology Imaging Solutions. Both acquisitions arose out of our M&A funnel generation program that has been developed and refined over the last year. Slides four and five provide a brief overview of each. Z-Sciences was a small tuck-in asset acquisition, which closed on October 6 and was funded with cash on hand. The acquisition is an ideal demonstration of our strategy to grow through innovative technologies with an eye toward fast-growing adjacent markets, as it provided both a low-cost method for adding ultra-cold storage to our ultra-cold test solutions, and it allows us to gain a presence in a fragmented, but fast-growing estimated $200 million addressable market. Their portfolio of high-performance biomedical refrigerators and freezers are used to meet versatile applications, including ultra-cold storage solutions for biological sample banks, blood safety, vaccine safety, medical supplies, and reagent safety. Currently, there is little to no overlap in customer base, as their products are largely sold to research institutions, universities, pharmaceutical biotechnology manufacturers, and hospitals. While the current business has de minimis revenue, we believe we can build a scalable operation to accelerate growth and medical cold chain applications by leveraging our engineering expertise, manufacturing capabilities, and financial strength with targeted investments in sales and marketing as well as product innovation. Turning to Slide 5, and our most recent acquisition, Videology, which we acquired last week on October 28. The Videology acquisition is consistent with a number of our strategic initiatives, as it will help us expand our process technology solutions and diversify our reach into targeted Life Sciences and industrial markets while also broadening our international footprint and customer base. Additionally, this aligns with enhancing automation capabilities, as we will look to add future product solutions with imaging data and analytical tools in valuable functionality and expertise as inTEST strives to embrace opportunities created by the Internet of Things and making the most of artificial intelligence-based tools. Their product set includes industrial-grade circuit board mounted video digital cameras and related devices, systems, and software, which are used in a broad spectrum of applications. About 72% of their revenue is in the Life Sciences and security markets but they also serve aerospace, machine vision, biometrics, and diagnostic imaging industries. Customers include Fortune 500 Companies and government prime contractors, as well as mid-sized security, biotech, and machine vision OEMs and integrators. The company has a design and sales facility in the Netherlands and generates about 40% of the revenues from European customers. Similar to Z-Sciences, this too is a highly fragmented market that is large and growing. It is important to note that this is not a camera acquisition. It is about image-capture and data analysis that Videology brings. The company is similar to our other businesses in the sense that they develop highly valued engineered solutions. I want to briefly talk to a few application-specific examples to give you a sense of the technology we are adding. Videology supplies cameras in the ophthalmology markets to capture images of the inner eye to examine patients for refractive correction, glaucoma, and other degenerative eye diseases. Another example is spectroscopy applications, which are commonly used in chemical analysis to provide a structural fingerprint by which molecules can be identified. Videology cameras are used by a leading Fortune 500 Company in their handheld and tabletop devices providing this type of analysis. Finally, their small cameras are commonly used to inspect pipes of all diameters from large oil and gas pipes to small fiber optic applications. The medical applications for pipe inspections include medical intraoral endoscopes. What sets Videology apart from the competition is their design expertise and flexibility to work with customers on unique solutions. From a financial perspective, Videology's trailing 12-month revenue as of the end of September was approximately $10 million and provided comparable gross margins with inTEST. We expect the acquisition to be approximately $0.05 accretive to diluted earnings per share in the first year with inTEST. This is net of one-time acquisition-related expenses of approximately $0.03 per diluted share, which will be recognized in the fourth quarter of 2021. While we finance the Videology transaction with a portion of our new credit facility, we still have the financial flexibility and resources to continue to pursue a robust pipeline of acquisition opportunities. Lastly, Life Sciences is a key target market for inTEST and both of these acquisitions bring technology and engineering know-how that enhances our medical offerings in that space. Importantly, with some incremental investments and operational support, we believe we can scale these businesses and benefit from secular tailwinds in the Life Sciences markets. These are exciting times for inTEST as we drive change throughout the organization and build momentum by augmenting our deep industry knowledge, reputation, and expertise to develop and deliver more high-quality innovative solutions to address our customers' complex requirements. With that, let me now turn it over to Duncan to review our third quarter financials in more detail. Duncan, over to you.

Thank you, Nick. Starting on slide 6, we provide some detail regarding our top-line. Revenue for the third quarter was $21.1 million, a 46% increase over the same period last year and just above the midpoint of our guidance. Multi-market revenue grew 22% from the second quarter fueled by strength in the industrial market, while our semi business remains at historically high levels despite the sequential dip. We continue to see the benefit of our ongoing innovation and development efforts as our new product designs are being well-received in our markets. We are gaining new customers and winning business from competitors. Moving to slide 7, our third quarter gross margin of 49.2% was in line with guidance and compares with 50.2% in the second quarter of 2021 and 44.7% a year ago. When compared with the second quarter, the change in gross margin reflected higher component material costs not yet fully covered by price improvements as well as changes in product mix and less favorable absorption of fixed manufacturing costs. We continue to actively manage ongoing challenges of supply chain constraints and expect to start seeing some positive impact from the price increases we have rolled out in the second and third quarters; although we do not expect the full benefit of these initiatives will be felt until next year. Slide 8 details our operating expenses and expectations for the fourth quarter. Selling expense grew 9% sequentially to $2.8 million in the third quarter driven by increased headcount, a return to more normal levels of travel as restrictions are lifted, and an increase in spending on new advertising initiatives. Engineering and product development expense remained relatively unchanged compared with the trailing period. General and administrative expense decreased 4% sequentially to $3.6 million for the third quarter. Restructuring and other charges were $51,000 down from $197,000 in the second quarter. The third quarter included an increase in expenses related to M&A activities, but this was more than offset by the $324,000 reduction quarter-to-quarter related to non-recurring CFO transition costs in the second quarter, a sequential quarter reduction in costs associated with finalizing the integration of our EMS manufacturing operations, which is now complete, and a reduction in spend on non-M&A-related initiatives as focus on spending on M&A activities has ramped up. We expect operating expenses to trend up significantly in the fourth quarter reflecting the impact of the businesses acquired in October. In addition, we expect an incremental increase in costs related to acquisition activities of approximately $300,000 and incremental amortization related to acquired intangibles of approximately $100,000. You can see our bottom-line and adjusted EBITDA results on slide 9. We had net earnings of $2.2 million or $0.20 per diluted share for the third quarter, which was in line with guidance and compares with net earnings of $2.6 million or $0.24 per diluted share for the second quarter. We accrued income tax expense of $357,000 in the third quarter reflecting a 14% effective tax rate. This compares with $447,000 of income tax expense accrued in the second quarter, which reflected an effective tax rate of 15%. We expect our effective tax rate in 2021 will range from 14% to 16%. Diluted average shares outstanding were $10.8 million for the third quarter of 2021. During the third quarter, we saw 3,435 option shares exercised bringing the total for the nine months to 149,010, which has raised $1 million in cash proceeds this year. Adjusted EBITDA was $3.4 million for the third quarter compared with $4 million for the second quarter and $1 million during the prior period. Beginning with the third quarter, we are reporting adjusted EBITDA, which removes the impact of stock-based compensation from EBITDA. Stock-based compensation is a non-cash expense and as such does not impact our liquidity. Accordingly, we believe that our adjusted EBITDA is a better performance measure to assess the strength of our cash generation than EBITDA alone. More detail on the calculation of adjusted EBITDA can be found under non-GAAP financial measures in our earnings release. Consolidated headcount at September 30 was 232, an increase of 10 staff from the level we had at June 30. The increase was primarily in our Thermal segment. I'll now turn to Slide 10 for our capital structure and cash flow. As previously announced on October 18, we executed a new 5-year credit agreement with M&T Bank, which includes a $25 million non-revolving delayed draw term loan and a $10 million revolving credit facility. This new agreement replaced our existing $10 million facility with M&T Bank, which had no borrowings at quarter end. On October 28, we used $12 million under the term note to finance the acquisition of Videology. Cash and cash equivalents increased by $4.1 million sequentially to $18.7 million. We generated $4.3 million of cash from operations during the third quarter. We currently expect cash and cash equivalents to increase throughout the balance of 2021, subject to any strategic investments we may choose to make. Accounts receivable declined $600,000 or 5% sequentially to $12.2 million at September 30 with 53 DSO, down from 54 DSO at June 30. Inventories grew $657,000 or 8% sequentially to $9.4 million, primarily driven by raw material influx in our Thermal segment to support the increased Multimarket demand we are seeing. Capital expenditures during the third quarter were $114,000, up from $75,000 in the second quarter. We have no significant commitments for capital expenditures for the balance of 2021. However, depending upon changes in market demand or manufacturing and sales strategies, we may make purchases or investments as we deem necessary and appropriate.

Thanks, Duncan. Slide 11 highlights our orders and backlog. Overall, demand for our products and solutions remains strong and we continue to secure new orders in our targeted growth markets and are making inroads and working with OEMs to embed our solutions for broader market exposure. Orders for the third quarter were $21.1 million, a 47% increase over the same period last year and was supported by growth in both Multimarket and Semi Market. The year-over-year increase in Multimarket orders was primarily from the automotive industry, which includes the EV market. During the recent third quarter, we received a significant follow-on order for approximately $1 million from one of our EV customers, which we expect to ship over the next several quarters. As a reminder, in the second quarter of 2021, we received a record order for chillers from a key automotive OEM manufacturer for approximately $1.5 million. This order is also shipping over multiple quarters beginning in Q4. Note, this trend of placing larger orders that will ship over several quarters is one we are seeing with more frequency. We expect this may at times result in period-over-period fluctuations in order levels that are not necessarily indicative of changing demand but rather reflect the timing of when these large orders were placed. Our backlog at quarter-end was $20.4 million, approximately 75% of which is expected to convert to sales in the fourth quarter. Please turn to Slide 12 and I will provide an update on our near-term expectations. We will continue to execute on our five-point strategy with a focus on driving growth and diversifying our markets and customer base. Our recent acquisitions have added to our product platform offerings and technical expertise and expanded our customer base to adjacent high-growth markets. Integration efforts are well underway on both businesses. As to guidance for the fourth quarter of 2021, we expect revenue to be in the range of $21.5 to $22.5 million, while gross margins are expected to be consistent with what we achieved in the third quarter. Also, we are guiding to GAAP EPS of $0.10 to $0.14 per diluted share and adjusted non-GAAP EPS of $0.14 to $0.18 per diluted share for the fourth quarter of 2021. While we do not plan to provide specific detail around expenses each quarter, Duncan did provide our expectations for the fourth quarter operating expenses as we thought it was prudent to help our investor base understand the new run rates and costs associated with our recent acquisition activity. Our guidance is based on our current views with respect to operating and market conditions and customer forecast, which are subject to change as well as our expectations for the balance of the quarter and are subject to any strategic investments we may choose to make. Actual results may differ materially as a result of among other things, the factors described under forward-looking statements found in the materials that accompany this conference call, including the press release and the deck. Our M&A funnel development is still very active and we continue to be focused on programmatic acquisitions being a key element of our five-point strategy. Our team has identified a set of acquisition targets that we believe will bring differentiated or innovative technologies, provide complementary capabilities or enable deeper and broader reach within our targeted industries and geographies. To support our focus in this area, we are pleased to have added Rich Rogoff as our Vice President of Corporate Development, at the start of the fourth quarter. Rich brings experience on the deal pursuit side and a strong operational background to support our integration activities. We also expect to grow organically through new product development, sales channel enhancements, and marketing prowess. We believe our efforts combined with a robust pipeline of new customer opportunities can provide further differentiation to our business and drive growth and profitability over the longer term. We are excited about what's happening at inTEST and the path we have embarked on with our five-point strategy. Before I open up the lines for Q&A, I would like to thank the entire inTEST team for delivering another truly solid quarter. The teams remain laser-focused on capturing growth and driving investments that will position us well long-term. With that, operator, let's now open the lines for questions.

Thank you. At this time, we will be conducting a question-and-answer session. Our first question comes from the line of Jaeson Schmidt with Lake Street Capital Markets. Please proceed with your question.

Hey guys. Thanks for taking my questions. I just want to start with that Q4 guidance. Nick, I know you mentioned about $500,000 in orders that we were unable to ship in Q3, but does guidance for Q4 assume you can ship to all of the demand or is that still baking in some potential supply chain constraints?

Good morning, Jaeson, and that's a great question. As we mentioned, there are significant supply chain constraints out there. We believe that our guidance for Q4 takes into account the potential risks posed by these supply chain issues. Duncan, do you have any comments on that?

No, I totally agree. We certainly have assumed in that number, the challenges that we see from a supply chain perspective and have factored that into the numbers.

Okay. That’s very helpful. I apologize if I missed it, but what sort of contribution do you expect from the acquisitions? I know you said, Z-Sciences is relatively de minimis revenue but what revenue contribution from the combined two purchases in Q4?

Yeah. We're looking at around $1.5 million in that order of magnitude all from Videology. Z-Sciences, there is some incremental costs associated with getting the Z-Sciences product line up and running in Q4 order of magnitude $0.01 to $0.015, I'd say associated with that. Videology, as I said, about $1.5 million is baked into our assumption there, with no real bottom-line contribution in the initial quarter. And we also have the M&A-associated costs of the $0.03 that we have talked about and called out.

Okay. And just the last one for me and I'll jump back into queue. Congrats on that $1 million EV order. Just curious if you could provide some color around why you're thinking why you think you're starting to see some of these larger orders get pulled over the finish line?

It's a trend out there, as customers are really working to ensure they've got a slot in the delivery pattern, if you will, given the supply chain constraints and that. So in this case, that EV customer really is building out their production lines and they wanted to go ahead and get all the units on order for that line, which we'll deliver over the next few quarters. So – but I just think, it's more risk management from the customer perspective.

Okay. That makes sense. Thanks a lot, guys.

Thank you. Our next question comes from the line of Dick Ryan with Collier Securities. Please proceed with your question.

Thank you. So Nick, you initiated a pretty aggressive marketing campaign in Multimarket I guess specifically at Ambrell going after induction heating. Can you provide an update, how that's going? I know we just kicked off, I think last quarter, but what are you seeing as far as potential customers or existing customers' response to that campaign?

Yeah. Hey, good morning, Dick. Dick, great question there. And you're exactly right. We launched a couple of aggressive campaigns, one at Ambrell focused on the EV build-out and capturing as much opportunity as we can there. And the second one was in the cannabis space with our iTS business. And specific to Ambrell, the program itself has generated an attractive level of qualified leads. They've actually got programs underway with multiple new potential customers. As you saw during your visit up there, we get these applications from these customers. We have to prove them out in our lab. And then from that point, it leads to implementation and production, if they're satisfied with that. And that's exactly where we're at is doing the application best getting, if you will, and proving out this. So I'm very confident, these are going to pay off here in the quarters ahead.

Okay. Specifically on the Semi side, I think last call you talked about the digestion and we saw that in the September quarter. What's your view of your Semi in Q4, and maybe going into Q1 both the back-end legacy EMS, but also Ambrell's front-end opportunities?

Yeah. Semi got a number of positive secular trends and announced investment plans and everything else. So we're very bullish on Semi going into 2022. We continue to see solid activity on the front-end side on rest silicon carbide even in our test piece on the back-end side, the temperature test chambers are instruments that we provide high levels of activities there, and customers are more of our traditional test on the EMS side are ramping up their plans or laying out their plans for 2022, which we're closely engaged with them on. So we feel good heading into 2022 on Semi.

Okay. And on the acquisitions, I think you talked about in both opportunities scaling what these companies have developed and grown to this point. Some of these are new market touchpoints for you. How do you have the visibility that you can scale into some of these new market opportunities?

Yeah. A great question. Absolutely, both of these acquisitions we completed really open up some new markets for us and attractive markets. The Life Sciences space is one that we targeted as an area we wanted to go after as part of a corporate growth program and identifying Z-Sciences, really a company with great technology, able to bring in an industry expert to help us penetrate this space, with that acquisition, and providing some low-cost manufacturing through an outsourced agreement there. Really positions us in a different place for our iTS business, but we believe our ultra-low-temperature capabilities and know-how, and our sales and marketing prowess, if you will, will drive this business to the levels that we can get to on there. And same for Videology; this is a bigger play around data capture, building out our automation capabilities and further strengthening our footprint in Life Sciences. And so, it's not a market that I'm unfamiliar with. While, in my days at AMETEK, I oversaw a camera company, a video capture company. And so I know this space, I think we'll do quite well in it.

Okay. Great. Good luck and congratulations.

Thank you. Our next question comes from the line of Peter Wright with Intro-act Inc. Please proceed with your question.

Thank you, guys for taking my questions, and congratulations on what looks like $100 million year. Nick for your first. So that's quite an accomplishment. My first question for you is a two-parter. You did signal no customer overlap and building on Dick's question, what is the go-to-market or sales strategy in Life Sciences? Is it direct? Are you working with distributors there? And if you could comment on what your belief of the cross-sell of your existing product into that new market could be. How are you thinking about that from a size perspective? And then the second part of that question for you Nick is on the Z-Sciences side. Is that simply a technology acquisition or do you have line-of-sight to first sales for that business?

Yes, great question, Peter, and good morning. The go-to-market strategy for these businesses, as we mentioned, involves entering markets where we currently don't have a strong presence. Our approach will leverage the existing distributor network they've built in relation to Z-Sciences while also investing in direct sales channels to effectively communicate our message and enhance product supply in those regions. We will make investments to strengthen this and provide our go-to-market expertise around those businesses. Videology has a similar approach, mainly selling through OEMs, and this represents a vast market. We believe that by targeting specific niches in this space, we can really make progress, but it's essential to integrate our product with OEMs in that area. We've initiated similar efforts across our other businesses and are confident we can succeed in this area as well.

Do you have any estimates on the incremental sales from your existing product portfolio before the acquisitions? Do you believe these two acquisitions will aid in selling in this channel?

To be honest, there isn't much demand for our existing products in these channels. We will try to see if there are any opportunities, but in reality, these vaccine freezers and refrigerators typically don't use EMS-type products or induction heating, and they are generally not found in universities, medical centers, or pharmaceutical facilities. However, if an opportunity arises, we will pursue it. For us, the focus is on growing opportunities, identifying leads, and expanding our presence in relation to these two companies.

Phenomenal, and then my two-parter if I can for Duncan, OpEx of $9 million to $9.2 million; is that a full quarter of expenses for the two acquired businesses? I know you've got $300,000. Thanks for the breakdown on that, by the way of deal offset. So is that a good number to be thinking of going forward? And then the second part, if you could just check my math on the cash. You've got a $35 million line of credit, $12 drawn which leaves about $23 million available and about $20-ish million at the end of the year. Does that suggest about $40 million of liquidity exiting the year? And my question there is if the math is right and then what is the minimum number of liquidity that you really need to be comfortable with inTEST?

Sure. Let me address the first part. Regarding expenses, it's nearly fully loaded. We have only two months of Videology included instead of three. So, I would estimate an additional $100,000 to $150,000 to add to the existing range of $9 million to $9.2 million. When I exclude the deal costs we mentioned earlier, I think it aligns more with the $8.5 million range. To clarify, we have a total of $600,000 in M&A-related deal costs included in the Q4 figure, which comes from Videology as well as other activities related to Z-Sciences and so on. I hope that provides some clarity. On the liquidity side, yes, we have a cash position of around $19 million at the end of the quarter. We established a funding facility for the $25 million delayed draw; the $10 million credit facility was simply an extension of our existing credit arrangements. We have drawn $12 million from the $25 million. In response to Peter's question, we are constantly seeking additional liquidity. If we find opportunities to extend credit lines, we will certainly pursue those. Overall, we have made a good start with the funding and facilities established during the third quarter, or at the start of the fourth quarter, rather.

Great quarter. Thank you, guys.

Thanks, Peter.

Thank you. Our next question comes from the line of Robert Marcin with Penn Capital. Please proceed with your question.

Congratulations, guys on another strong quarter of execution, particularly the cash flow numbers which were exceptional.

Hey, thanks Robert.

Assuming the semiconductor business stabilizes at a high level for the next year before starting to grow again after this year's significant capital investment, do you believe your initiatives to boost growth in the EMS and thermal sectors will lead to any revenue growth this year? It has been about a year since you joined and began working to shift the corporate culture towards a more growth-oriented approach. Can you provide any specifics on revenue that exceeds what would have been produced under previous management from your efforts?

Yes. Good question. And we laid out our five-point strategy and we're driving that across all businesses, but EMS is really making some great inroads. Customer penetration, expansion into new customers, going into new markets with their high-voltage high-current product out there; this power management integrated circuit space is an area that hadn't played in the past and we're really making some good inroads there. So I truly believe what we're driving across the business also some investments that are planned in further geographic expansion for that business. And so, I believe we've got plenty of room to grow in that business, whether or not the overall market trends are moving up or down.

Thank you. Congratulations again on two very reasonable deals that appear to have significant long-term opportunities. Would you be willing to provide a three-year sales outlook for both of those businesses if you succeed?

At this stage, it's a little too early to provide that forecast. We absolutely expect to grow these. I hope you understand that I'm focused on growth and identifying these markets, as well as these companies, at reasonable purchase prices that align with creating shareholder value. I'm confident that the markets, opportunities, and investments we've identified will drive growth for both businesses. However, I believe our Investor Day, which we're planning for the end of Q1, will offer more details. We had to delay it due to the situation in New York, but we'll provide the full year and the five-year strategic plan expectations during that time.

Thank you. You provided a total addressable market for the healthcare sector related to Videology. Could you also provide one for that? You mentioned one for Z, I believe.

Yes, Z-Sciences has a total market of about $500 million, but our served market is really around $200 million. The image capture product space is enormous, exceeding $20 billion. The segment we operate in with Videology is approximately $5 billion. We believe that by focusing on just 10% of that market, we can achieve significant growth and make substantial progress.

Thank you. And my last question, at times when investors are concerned or foolish about the semiconductor cycle that stock seems to sell off to stupidly low valuations. Have you guys considered having in your quiver a share repurchase program that could exploit these sudden declines in the stock and at least cover stock option issuance, or something modest from a repurchase program? Thank you.

We've certainly done that in the past, and we're always looking at where would it make sense to perhaps do that. We do need also to be cognizant of cash requirements and looking at our pipelines and what we want to do with that. But absolutely, it's certainly something that's on our mind.

There's enough organic and inorganic growth opportunities, we don't want you to use cash with a programmatic share repurchase program. I would assume most shareholders, I speak for them to that. But at times, if the stock just gets pretty cheap it wouldn't hurt to have an availability to scrap some stock back at very low valuations when you will have obviously, annual dilution from your stock comp packages?

Yes, I agree, Robert. We do have an open share repurchase plan in place, but we haven't activated it yet.

All right. Thank you very much.

Great, Robert. Thanks.

Ladies and gentlemen, this concludes today's question-and-answer session. I'll turn the floor back to Mr. Grant for any final comments.

All right. Thank you and thanks everyone for joining us on the call today and for your interest in inTEST. For those of you interested, we will be participating in a few upcoming conferences. On November 18, we will be at the Virtual Ladenburg Dalman Technology Expo. On December 8, we'll be at the CEO Summit at the St. Regis, in San Francisco, which is coincident with the Semicon West Exhibition that's going on. And then on December 15, at the Virtual D.A. Davidson Conference. As always please feel free to reach out to us at any time and we look forward to talking with all of you again in early March, to report on our fourth quarter 2021 results. Thank you for your participation. Stay safe and have a great day.

This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.